Patents by Inventor Xiaoling Chen

Xiaoling Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
    Patent number: 10233160
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: March 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste DeSelm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20190023687
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 17, 2018
    Publication date: January 24, 2019
    Inventors: Brian A. SHERER, Nadia BRUGGER, Ruoxi LAN, Xiaoling CHEN
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 10087166
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • Heterocyclic carboxamides as modulators of kinase activity
    Patent number: 10080753
    Abstract: The invention provides novel heterocyclic carboxamide compounds according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Yufang Xiao, Ruoxi Lan, Lizbeth Celeste De Selm, Constantin Neagu, Justin Potnick, Srinivasa R. Karra, Theresa L Johnson
  • Aminopyrimidine derivatives for use as modulators of kinase activity
    Patent number: 10080750
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
  • AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES
    Publication number: 20180237402
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: August 23, 2018
    Inventors: Bayard R. HUCK, Ruoxi LAN, Justin POTNICK, Lizbeth Celeste DESELM, Mark W. CRONIN, JR., Constantin NEAGU, Xiaoling CHEN, Roch BOIVIN, Theresa L. JOHNSON, Andreas GOUTOPOULOS
  • Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors
    Patent number: 9981925
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste Deselm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Novel Heterocyclic Derivatives as Modulators of Kinase Activity
    Publication number: 20180072757
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Inventors: Ruoxi LAN, Bayard R. HUCK, Xiaoling CHEN, Yufang XIAO
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20180037570
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Application
    Filed: August 7, 2017
    Publication date: February 8, 2018
    Inventors: Brian A. SHERER, Xiaoling CHEN, Esther CLEARY, Nadia BRUGGER
  • Heterocycles as modulators of kinase activity
    Patent number: 9867826
    Abstract: The invention provides novel heterocyclic amines according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 16, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Xiaoling Chen, Yufang Xiao, Bayard R. Huck, Andreas Goutopoulos
  • Heterocyclic derivatives as modulators of kinase activity
    Patent number: 9850255
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 26, 2017
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Yufang Xiao
  • Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Patent number: 9815836
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Henry Yu, Ruoxi Lan, Catherine Jorand-Lebrun, Theresa L. Johnson, Andreas Goutopoulos
  • Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof
    Publication number: 20170275284
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Inventors: Xiaoling CHEN, Henry YU, Ruoxi LAN, Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Andreas GOUTOPOULOS
  • AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY
    Publication number: 20170217905
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 3, 2017
    Inventors: Ruoxi LAN, Bayard R. HUCK, Xiaoling CHEN, Lizbeth C. DESELM, Hui QIU, Yufang XIAO, Constantin NEAGU, Igor MOCHALKIN, Theresa L. JOHNSON
  • Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Patent number: 9708324
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Henry Yu, Ruoxi Lan, Catherine Jorand-Lebrun, Theresa L. Johnson, Andreas Goutopoulos
  • PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20170173019
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 22, 2017
    Inventors: Xiaoling CHEN, Ruoxi LAN, Catherine JORAND-LEBRUN, Henry YU, Andreas GOUTOPOULOS
  • Aminopyrimidine derivatives for use as modulators of kinase activity
    Patent number: 9662330
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 30, 2017
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
  • Cyclic Amine Azaheterocyclic Carboxamides
    Publication number: 20170129877
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Bayard R. HUCK, Xiaoling CHEN, Constantin NEAGU, Reinaldo JONES, Yufang XIAO, Igor MOCHALKIN
  • Pyridazinone macrocycles as IRAK inhibitors and uses thereof
    Patent number: 9624246
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 9586938
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: March 7, 2017
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin